A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors

NCT06515613 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

80

Enrollment

INDUSTRY

Sponsor class

Conditions

Platinum-resistant Ovarian Cancer
Testicular Cancer
Endometrial Cancer

Interventions

DRUG: CTIM-76

Sponsor

Context Therapeutics Inc.